MedPath

Amgen, Inc.

Amgen, Inc. logo
🇺🇸United States
Ownership
Public
Established
1980-01-01
Employees
26.7K
Market Cap
$175.6B
Website
http://www.amgen.com
Clinical Trials
Related News

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Phase 3
Completed
Conditions
Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Interventions
Biological: AMG 531
Drug: Placebo
First Posted Date
2005-01-28
Last Posted Date
2022-11-07
Lead Sponsor
Amgen
Target Recruit Count
63
Registration Number
NCT00102323

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Phase 1
Terminated
Conditions
Lung Cancer
Pancreatic Cancer
Esophageal Cancer
Interventions
Biological: Panitumumab
First Posted Date
2005-01-19
Last Posted Date
2014-03-20
Lead Sponsor
Amgen
Target Recruit Count
41
Registration Number
NCT00101907

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Rectal Cancer
Colon Cancer
Interventions
Drug: FOLFOX-4
Biological: Panitumumab (Part 1a only)
Drug: FOLFIRI
First Posted Date
2005-01-19
Last Posted Date
2012-09-17
Lead Sponsor
Amgen
Target Recruit Count
119
Registration Number
NCT00101894

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Neoplasm Metastasis
Lung Cancer
Interventions
First Posted Date
2005-01-19
Last Posted Date
2010-10-15
Lead Sponsor
Amgen
Target Recruit Count
50
Registration Number
NCT00101920

Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)

Phase 4
Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2004-12-17
Last Posted Date
2009-11-13
Lead Sponsor
Amgen
Target Recruit Count
200
Registration Number
NCT00099554

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

Phase 3
Completed
Conditions
Kidney Disease
Chronic Kidney Disease
Interventions
First Posted Date
2004-11-18
Last Posted Date
2009-05-22
Lead Sponsor
Amgen
Target Recruit Count
110
Registration Number
NCT00096915

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: placebo
First Posted Date
2004-11-08
Last Posted Date
2021-10-25
Lead Sponsor
Amgen
Target Recruit Count
227
Registration Number
NCT00095498

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Phase 2
Completed
Conditions
Anemia
First Posted Date
2004-11-03
Last Posted Date
2009-03-13
Lead Sponsor
Amgen
Target Recruit Count
220
Registration Number
NCT00095277

A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
First Posted Date
2004-11-03
Last Posted Date
2010-01-15
Lead Sponsor
Amgen
Target Recruit Count
209
Registration Number
NCT00095264

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Completed
Conditions
Lung Cancer
Non-Small Cell Lung Cancer
Interventions
Biological: Panitumumab
First Posted Date
2004-10-27
Last Posted Date
2016-03-24
Lead Sponsor
Amgen
Target Recruit Count
51
Registration Number
NCT00094835
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy